Vanda Pharmaceuticals
VNDA
₹407.53
Share price
-0.43%
Change (1 day)
-18.89%
Change (1 year)
Categories
Vanda Pharmaceuticals (VNDA) - Total liabilities
Total liabilities on the balance sheet as of March 2025 : ₹10.49 Billion
According to Vanda Pharmaceuticals's latest financial reports the company's total liabilities are ₹10.49 Billion. A company’s total liabilities is the sum of all current and non-current debts and obligations.
Vanda Pharmaceuticals - Total liabilities on balance sheet (from 2005 to 2025)
Total liabilities by year
| Year | Total liabilities | Change |
|---|---|---|
| 2024-12-31 | ₹10.09 B | 17.11% |
| 2023-12-31 | ₹8.61 B | -2.7% |
| 2022-12-31 | ₹8.85 B | 33.93% |
| 2021-12-31 | ₹6.61 B | 12.78% |
| 2020-12-31 | ₹5.86 B | 12.96% |
| 2019-12-31 | ₹5.19 B | 30.93% |
| 2018-12-31 | ₹3.96 B | -16.12% |
| 2017-12-31 | ₹4.72 B | -11.99% |
| 2016-12-31 | ₹5.37 B | 1.01% |
| 2015-12-31 | ₹5.31 B | 670.72% |
| 2014-12-31 | ₹0.68 B | -88.74% |
| 2013-12-31 | ₹6.13 B | -10.82% |
| 2012-12-31 | ₹6.87 B | -12.88% |
| 2011-12-31 | ₹7.88 B | 0.4% |
| 2010-12-31 | ₹7.85 B | -16.44% |
| 2009-12-31 | ₹9.40 B | 4899.58% |
| 2008-12-31 | ₹0.18 B | -63.5% |
| 2007-12-31 | ₹0.51 B | 22.44% |
| 2006-12-31 | ₹0.42 B | 83.84% |
| 2005-12-31 | ₹0.22 B | 192.3% |
| 2004-12-31 | ₹78.32 M |
Total liabilities for similar companies or competitors
| Company | Total liabilities | differencediff. | Country |
|---|---|---|---|
 Novartis NVS | ₹5.354 T | 50,920.17% | 🇨🇭 Switzerland |
 Eli Lilly LLY | ₹6.404 T | 60,921.08% | 🇺🇸 USA |
 Johnson & Johnson JNJ | ₹10.063 T | 95,786.96% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | ₹6.529 T | 62,113.43% | 🇺🇸 USA |
 Pfizer PFE | ₹10.222 T | 97,304.56% | 🇺🇸 USA |
 Titan Pharmaceuticals
TTNP | ₹24.29 M | -99.77% | 🇺🇸 USA |
 Merck MRK | ₹5.810 T | 55,262.23% | 🇺🇸 USA |